Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) Short Interest Down 66.5% in July

Rocket Pharmaceuticals, Inc. (NASDAQ:RCKTW) was the recipient of a large decline in short interest in July. As of July 31st, there was short interest totaling 49,126 shares, a decline of 66.5% from the July 15th total of 146,438 shares. Based on an average daily volume of 92,986 shares, the days-to-cover ratio is presently 0.5 days.

Rocket Pharmaceuticals Stock Performance

Shares of Rocket Pharmaceuticals stock traded down $0.00 during midday trading on Friday, hitting $0.00. The company had a trading volume of 10,566 shares, compared to its average volume of 39,248. Rocket Pharmaceuticals has a 52-week low of $0.00 and a 52-week high of $0.08.

Rocket Pharmaceuticals Company Profile

Rocket Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, life-transforming gene therapies for rare pediatric diseases. The company’s research and development activities center on inherited genetic disorders, leveraging both lentiviral and adeno-associated virus (AAV) platforms to deliver corrective genes. Rocket’s lead programs include treatments for conditions such as Fanconi anemia, leukocyte adhesion deficiency-I (LAD-I), Danon disease and mucopolysaccharidosis type IIIA (MPS IIIA), each of which represents a high unmet medical need in the pediatric population.

Founded in 2015, Rocket Pharmaceuticals went public in 2018 and trades on the Nasdaq under the ticker symbol RCKTW.